Peptides

Tesamorelin vs Sermorelin: Which GH Peptide Is Right for You?

Medically reviewed by Medical Advisory Board Last reviewed 2026-05-13

FDA-approved GHRH analogs compared by evidence, cost, and use case

Both tesamorelin and sermorelin stimulate the pituitary to release growth hormone, but they differ significantly in clinical evidence, cost, and availability. Tesamorelin has stronger trial data; sermorelin is far more affordable and widely prescribed.

Tesamorelin and sermorelin are both FDA-approved GHRH analogs that stimulate the pituitary to release growth hormone — but they were developed for different indications, have different evidence bases, and are priced dramatically differently. Understanding these differences helps determine which is appropriate for a given patient.

Tesamorelin vs Sermorelin: Full Comparison

FactorTesamorelin (Egrifta)Sermorelin
FDA approvalYes — HIV-associated lipodystrophy (2010)Yes — pediatric GH deficiency (1997)
MechanismModified GHRH analog (longer half-life)GHRH 1-29 analog (natural sequence)
Half-life~26 minutes~12 minutes
Clinical evidenceMultiple Phase III RCTs (visceral fat, IGF-1)Decades of off-label clinical use, observational data
Visceral fat data15–25% reduction in RCTsLess studied, clinically observed
Brand name cost$3,000–5,000/monthOff-patent; compounded $150–400/month
AccessPrescription required; limited compounding availabilityPrescription required; widely compounded
StackingUsually standalone (no GHRP typically added)Often stacked with ipamorelin for synergy

Which to Choose

Choose tesamorelin if:

  • You have HIV-associated lipodystrophy (FDA-indicated use)
  • Visceral fat reduction is the primary goal and cost is not a barrier
  • You're in an institutional setting where the FDA-approved agent is preferred

Choose sermorelin if:

  • Cost is a consideration ($150–400/month compounded vs. $3,000–5,000/month for brand tesamorelin)
  • You want to stack with a GHRP (ipamorelin) for synergistic GH stimulation
  • You're working with a functional/anti-aging physician who is familiar with sermorelin protocols
  • Broad GH optimization (not specifically visceral fat) is the goal

Frequently Asked Questions

Is tesamorelin better than sermorelin?

Tesamorelin has stronger clinical evidence (Phase III RCTs) specifically for visceral fat reduction. However, sermorelin is far more affordable, widely available through compounding pharmacies, and can be stacked with ipamorelin for synergistic GH stimulation. For most non-HIV patients, sermorelin (often with CJC-1295/ipamorelin) offers comparable GH optimization at a fraction of the cost.

What is the difference between tesamorelin and sermorelin?

Both are GHRH analogs that stimulate pituitary GH release. Key differences: tesamorelin has a slightly longer half-life, stronger Phase III trial evidence specifically for visceral fat, and is only FDA-approved for HIV lipodystrophy. Sermorelin has been used off-label for adult GH optimization for decades, costs dramatically less, and is more widely available through compounding pharmacies.

Topic updates

Get the weekly peptide roundup

Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.

No spam. Unsubscribe anytime.

M
Medically Reviewed
Medical Advisory Board
Board-Certified Physician
Last reviewed: 2026-05-13
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results

Continue Reading

← Back to Peptide Therapy

Understand your health — on your terms

Use our free tools and evidence-based guides to make smarter decisions about your metabolism, hormones, and recovery.

Take the Free Assessment →